{
    "config": {},
    "inference_duration_sec": 308.10464882850647,
    "evaluation_metrics": {
        "precision": 1.0,
        "recall": 0.5555555555555556,
        "f1_score": 0.7142857142857143,
        "auroc": 1.0,
        "auprc": 1.0,
        "num_samples": 10,
        "num_positive_true": 9,
        "num_positive_predicted": 5,
        "avg_lipschitz_constant": 42.0
    },
    "finetuning_performed": false,
    "finetune_duration_sec": "N/A",
    "sample_predictions": [
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046048.0,
            "PredictedProb": 0.8,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### Analysis of the Patient's EHR Data\n\n#### 1. **Recent Glucose Readings and Trends**\n- **2044879.0** - Glucose Bld-mCnc: **85.0 mg/dL**\n- **2045213.0** - Glucose Bld-mCnc: **142.0 mg/dL**\n- **2045659.0** - Glucose Bld-mCnc: **307.0 mg/dL**\n- **2045920.0** - Glucose Bld-mCnc: **257.0 mg/dL**\n- **2044492.0** - Glucose Bld-mCnc: **177.0 mg/dL**\n- **2044153.0** - Glucose Bld-mCnc: **231.0 mg/dL**\n- **2043805.0** - Glucose Bld-mCnc: **126.0 mg/dL**\n\nThere is a **clear trend of fluctuating glucose levels**, with a **recent sharp drop** from **307 mg/dL (2045659.0)** to **257 mg/dL (2045920.0)**, and now to **85 mg/dL (2044879.0)**. The last recorded glucose level is **85 mg/dL**, which is **significantly low** and near the hypoglycemic threshold of **<54 mg/dL**.\n\n#### 2. **Medication Use and Dosing**\n- **Insulin isophane (NPH)** and **insulin regular** are frequently administered. Insulin is a well-known cause of hypoglycemia when dosing is too high or timing is off relative to food intake.\n- **2043808.0** - insulin isophane, human 100 UNT/ML Injectable Suspension\n- **2044493.0** - insulin, regular, human 100 UNT/ML Injectable Solution\n- **2045218.0** - insulin isophane, human 100 UNT/ML Injectable Suspension\n- **2045660.0** - insulin isophane, human 100 UNT/ML Injectable Suspension; insulin, regular, human 100 UNT/ML Injectable Solution\n\nThe frequent use of **insulin** increases the **risk of hypoglycemia**, especially in the absence of clear documentation of food intake or glucose monitoring after administration.\n\n#### 3. **Patient History and Risk Factors**\n- No clear documentation of **diabetes duration**, **hypoglycemia unawareness**, or **renal/hepatic impairment**.\n- However, the patient is receiving **insulin** and has **recently experienced very high glucose levels (307 mg/dL)**, which may indicate **overcorrection** or **aggressive treatment**, increasing the risk of **recurrent hypoglycemia**.\n- The presence of **renal function markers** (e.g., creatinine: 0.51 mg/dL at 2045916.0) suggests **normal kidney function**, which is **protective** against hypoglycemia in insulin-treated patients.\n\n#### 4. **Symptoms and Clinical Context**\n- No symptoms of hypoglycemia (e.g., sweating, confusion, dizziness) are explicitly documented.\n- The patient appears to be in an **inpatient setting** based on the frequency and complexity of interventions (e.g., lab panels, medications, respiratory support), but the task is to assess **outpatient hypoglycemia risk**.\n\n#### 5. **Other Considerations**\n- The last recorded glucose is **85 mg/dL**, which is **very close to the hypoglycemic threshold**, and the **rate of decline** from 307 to 85 mg/dL is **concerning**.\n- The patient is receiving **insulin without clear evidence of food intake or carbohydrate intake** being documented, which increases the **risk of further glucose decline**.\n- The **absence of glucose-raising interventions** (e.g., oral glucose, dextrose) in the recent history is **not reassuring**.\n\n---\n\n### Final Prediction\n\nGiven the **recent glucose drop to 85 mg/dL**, the **use of insulin**, and the **lack of documented glucose-raising measures**, the patient is at **high risk of hypoglycemia within the next hour**.\n\n**Prediction: Yes, Risk: 0.80**"
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046088.0,
            "PredictedProb": 0.92,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n2046088.0 - sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 45.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.4\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### Analysis of the Patient's Data\n\n#### 1. **Recent Glucose Readings and Trends**\n- **2044879.0** - Glucose Bld-mCnc: **85.0 mg/dL** (1.5 mmol/L)\n- **2045213.0** - Glucose Bld-mCnc: **142.0 mg/dL** (7.9 mmol/L)\n- **2045659.0** - Glucose Bld-mCnc: **307.0 mg/dL** (17.0 mmol/L)\n- **2045920.0** - Glucose Bld-mCnc: **257.0 mg/dL** (14.3 mmol/L)\n\nThere is a **significant and recent drop in glucose levels** from **307 mg/dL** to **257 mg/dL** to **85 mg/dL**, indicating a **rapid decline in blood glucose**. The most recent reading is **85 mg/dL**, which is **very close to the hypoglycemic threshold** of 54 mg/dL. The trend suggests a **steep downward trajectory**, which is a **high-risk indicator** for hypoglycemia in the next hour.\n\n---\n\n#### 2. **Medication Use**\n- **Insulin isophane (NPH)** and **insulin regular** are both used.\n  - NPH insulin has a **peak effect 4\u201312 hours after administration**.\n  - Regular insulin peaks **2\u20134 hours post-injection**.\n- There are **multiple insulin administration records**:\n  - **2043808.0** - insulin isophane\n  - **204493.0** - insulin, regular\n  - **2045218.0** - insulin isophane\n  - **2045660.0** - both isophane and regular insulin\n- The most recent insulin administration was at **2045660.0**, and the next data point is **2045676.0**, with **2045659.0** (307 mg/dL) and **2045920.0** (257 mg/dL) as glucose readings in between. This indicates that **insulin is likely still active**, and the **rapid drop in glucose** is likely due to **excess insulin** or **inadequate carbohydrate intake**.\n\n---\n\n#### 3. **Risk Factors for Hypoglycemia**\n- **Rapid glucose decline** from 307 mg/dL to 85 mg/dL in a short time frame.\n- **Insulin use** (especially isophane and regular), with recent administration.\n- **No clear evidence of recent carbohydrate intake** in the EHR data.\n- **No evidence of hypoglycemic symptoms** reported (e.g., sweating, confusion), but this could indicate **hypoglycemia unawareness**, a known risk factor.\n- **Normal renal function** (creatinine = 0.47\u20130.51 mg/dL), so insulin clearance is not impaired.\n\n---\n\n#### 4. **Protective or Mitigating Factors**\n- **No recent meal or carbohydrate intake** is documented.\n- **No counter-regulatory interventions** (e.g., glucagon, glucose administration) are noted.\n- **No hypoglycemic symptoms** are reported, but this could be due to **unawareness** rather than absence of hypoglycemia.\n\n---\n\n#### 5. **Synthesis and Prediction**\n- The **rapid drop in blood glucose** from 307 mg/dL to 85 mg/dL is **extremely concerning**.\n- The **use of both isophane and regular insulin** suggests **tight glycemic control**, which increases the risk of hypoglycemia.\n- The **last recorded glucose is 85 mg/dL**, and the **rate of decline is steep**.\n- There is **no evidence of carbohydrate intake** or hypoglycemic symptoms.\n- Given the **current glucose level and trajectory**, the **risk of hypoglycemia (blood glucose < 54 mg/dL) in the next hour is high**.\n\n---\n\n### Final Prediction:\n**Prediction: Yes, Risk: 0.92**  \nThe patient is at **very high risk** of hypoglycemia within the next hour. Immediate monitoring and intervention are strongly recommended."
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046093.0,
            "PredictedProb": 0.85,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n2046088.0 - sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 45.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.4\n2046093.0 - dornase alfa 1 MG/ML Inhalation Solution\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### Step-by-Step Analysis:\n\n#### 1. **Recent Glucose Readings and Trends:**\n- **2044879.0 - Glucose Bld-mCnc: 85.0 mg/dL**\n- **2045213.0 - Glucose Bld-mCnc: 142.0 mg/dL**\n- **2045659.0 - Glucose Bld-mCnc: 307.0 mg/dL**\n- **2045920.0 - Glucose Bld-mCnc: 257.0 mg/dL**\n- **2044492.0 - Glucose Bld-mCnc: 177.0 mg/dL**\n- **2044153.0 - Glucose Bld-mCnc: 231.0 mg/dL**\n- **2043805.0 - Glucose Bld-mCnc: 126.0 mg/dL**\n\n**Observations:**\n- The most recent glucose measurement is **85 mg/dL**, which is near the hypoglycemic threshold of 54 mg/dL.\n- The glucose levels have been **fluctuating** significantly, with a **recent sharp decline** from **257 mg/dL (2045920.0)** to **85 mg/dL (2044879.0)**, indicating a **rapid decline**.\n- The glucose is **approaching the critical threshold**, and the **rate of decline is concerning**.\n\n#### 2. **Medications and Timing:**\n- **Insulin isophane (NPH)** and **insulin regular** are both used, indicating **intensive insulin therapy**.\n- **2043808.0 - insulin isophane administered**\n- **204493.0 - insulin, regular administered**\n- **2045218.0 - insulin isophane administered again**\n- **2045660.0 - both insulin isophane and regular administered**\n\n**Observations:**\n- The patient is receiving **multiple insulin injections**, which increases the **risk of hypoglycemia**, especially if the timing or dose is mismatched with food intake or activity.\n- No clear evidence of **recent carbohydrate intake** or **meal timing** is provided, increasing the risk of **insulin without glucose intake**.\n\n#### 3. **Patient History and Comorbidities:**\n- The data does not explicitly mention **previous hypoglycemic events**, **diabetes duration**, or **hypoglycemia unawareness**.\n- **No evidence of renal or hepatic impairment**, which could have contributed to insulin clearance issues.\n- **No reported symptoms of hypoglycemia** such as sweating, confusion, or dizziness are noted in the most recent entries.\n\n#### 4. **Protective Factors:**\n- **2045659.0 - Glucose 50 mg/mL Injectable Solution** was administered, suggesting a **glucose-raising intervention**.\n- However, the most recent glucose measurement is **85 mg/dL**, which suggests that the glucose may not have had enough time to elevate further or that the hypoglycemic trend is still ongoing.\n\n---\n\n### Risk Synthesis and Prediction:\n\n- The **most recent glucose is 85 mg/dL**, **very close to the hypoglycemic threshold**.\n- There is a **trend of rapid glucose decline**, from **257 mg/dL to 85 mg/dL**, indicating **significant risk**.\n- The patient is on **multiple insulin injections**, increasing the risk of **insulin-induced hypoglycemia**.\n- No evidence of **recent food intake**, and no **countermeasures** like carbohydrates are mentioned after the most recent glucose measurement.\n- **No symptoms of hypoglycemia** are reported, which could be a red flag for **hypoglycemia unawareness**.\n\n---\n\n### Final Prediction:\n**Prediction: Yes, Risk: 0.85**  \nThe patient is at **high risk** of experiencing a hypoglycemic event (blood glucose < 54 mg/dL) within the next hour due to a **rapid decline in glucose levels**, **recent insulin administration**, and **no protective factors like food intake or glucose-raising interventions** noted in the most recent data."
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046108.0,
            "PredictedProb": 0.85,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n2046088.0 - sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 45.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.4\n2046093.0 - dornase alfa 1 MG/ML Inhalation Solution\n2046108.0 - Resp rate: 46.0;Body temperature: 97.5;BP dias: 93.0;Body temperature: 37.4;Q-T interval corrected: 459.0;Heart rate: 128.0;Q-T interval: 312.0;Heart rate: 134.0;BP sys: 159.0;Bdy temp measurement site: 4.0;BP sys: 161.0;BP mean: 115.0\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### Analysis of the Patient Data\n\nThe data provided includes a detailed chronological record of the patient's medical history, vital signs, medications, and lab results. Here's a breakdown of the key factors that influence the risk of hypoglycemia within the next hour.\n\n---\n\n### 1. **Recent Blood Glucose Trends**\n- **2044879.0**: Glucose Bld-mCnc: **85 mg/dL** (7.2 mmol/L)\n- **2045213.0**: Glucose Bld-mCnc: **142 mg/dL** (7.9 mmol/L)\n- **2045659.0**: Glucose Bld-mCnc: **307 mg/dL** (17.0 mmol/L)\n- **2045920.0**: Glucose Bld-mCnc: **257 mg/dL** (14.3 mmol/L)\n- **2044492.0**: Glucose Bld-mCnc: **177 mg/dL** (9.8 mmol/L)\n\nThe most recent glucose reading is **85 mg/dL**, which is low but not yet hypoglycemic. However, the trend shows a **significant drop** from 307 mg/dL to 85 mg/dL in approximately **76 minutes**, indicating a **rapid decline** in blood glucose.\n\n---\n\n### 2. **Medications**\n- **Insulin isophane (NPH)** and **insulin regular** are both used. These are **intermediate and short-acting insulin**, respectively.\n- **Timing of insulin administration** is not explicitly provided, but multiple insulin administrations are recorded at various timestamps.\n- Insulin is a **primary risk factor** for hypoglycemia, especially if the patient has not consumed sufficient carbohydrates or is physically active.\n\n---\n\n### 3. **Risk Factors**\n- **Rapid glucose decline** from 307 mg/dL to 85 mg/dL in ~76 minutes.\n- **Insulin use** increases the risk of hypoglycemia, especially if the last dose was recent.\n- No clear documentation of **recent food intake** or **carbohydrate consumption**, which could stabilize glucose levels.\n- No mention of **hypoglycemia unawareness**, but the patient may be at risk due to prior episodes of low glucose.\n\n---\n\n### 4. **Protective Factors**\n- No clear documentation of **hypoglycemic symptoms** such as sweating, confusion, or dizziness at the most recent timestamp.\n- No mention of **glucagon administration**, suggesting the patient is not currently in a state of severe hypoglycemia.\n- The patient's **renal function** appears normal (e.g., creatinine is 0.47 mg/dL at 2044446.0), which is important for insulin clearance.\n\n---\n\n### 5. **Risk Synthesis & Prediction**\nThe patient is on **insulin therapy**, and their **blood glucose has dropped rapidly** from 307 mg/dL to 85 mg/dL in less than 2 hours. The most recent glucose is **85 mg/dL**, and the **trend is downward**. This pattern is **highly concerning**, especially in the context of insulin use and no clear carbohydrate intake.\n\nGiven the **rapid decline** and the **use of insulin**, the patient is at **high risk of hypoglycemia** within the next hour. The likelihood of a glucose level dropping below **54 mg/dL (3 mmol/L)** is significant.\n\n---\n\n### Final Prediction:\n**Prediction: Yes, Risk: 0.85**"
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": false,
            "TimeUpto": 2046109.0,
            "PredictedProb": 0.15,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n2046088.0 - sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 45.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.4\n2046093.0 - dornase alfa 1 MG/ML Inhalation Solution\n2046108.0 - Resp rate: 46.0;Body temperature: 97.5;BP dias: 93.0;Body temperature: 37.4;Q-T interval corrected: 459.0;Heart rate: 128.0;Q-T interval: 312.0;Heart rate: 134.0;BP sys: 159.0;Bdy temp measurement site: 4.0;BP sys: 161.0;BP mean: 115.0\n2046109.0 - chlorhexidine gluconate 1.2 MG/ML Mouthwash;acetaminophen 500 MG Oral Tablet\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### Analysis of the Patient's EHR Data\n\n#### **1. Blood Glucose Trends**\n- **Last recorded glucose level:** 257.0 mg/dL (at 2045920.0).\n- **Prior glucose readings:**\n  - 2045659.0: 307.0 mg/dL\n  - 2045213.0: 142.0 mg/dL\n  - 2044879.0: 85.0 mg/dL\n  - 2044492.0: 177.0 mg/dL\n  - 2044153.0: 231.0 mg/dL\n  - 2043805.0: 126.0 mg/dL\n\nThere is **no consistent downward trend** in glucose levels, and the most recent reading is **elevated**, indicating hyperglycemia rather than hypoglycemia.\n\n#### **2. Medication Use**\n- **Insulin isophane** and **insulin regular** are administered multiple times. These are long-acting and short-acting insulin, respectively.\n- However, the **timing of the most recent insulin dose** is **not clearly specified**, and the **last recorded glucose level is high**, suggesting that hypoglycemia is **unlikely** to occur imminently.\n- No mention of **sulfonylureas**, which are known to increase hypoglycemic risk.\n\n#### **3. Recent Interventions and Symptom Reporting**\n- No **symptoms of hypoglycemia** (e.g., sweating, shakiness, confusion) are reported in the most recent entries.\n- No **recent carbohydrate intake** is explicitly noted, but given the **elevated glucose levels**, it is likely that the patient has had recent food intake.\n\n#### **4. Laboratory and Clinical Parameters**\n- **Renal function (eGFR):** 105\u2013108 mL/min (normal range), indicating **no significant renal impairment**.\n- **Hemoglobin A1c is not explicitly mentioned**, but based on glucose trends, the patient is likely **hyperglycemic**.\n- **No signs of impaired counter-regulatory response** (e.g., glucagon deficiency).\n- **No signs of hypoglycemia unawareness** or prior hypoglycemic events.\n\n#### **5. Physical Activity and Other Factors**\n- No **recent physical activity** is noted.\n- No **alcohol use**, **fasting**, or **intercurrent illness** is reported.\n\n---\n\n### **Risk Synthesis and Prediction**\n- The **most recent glucose level is 257.0 mg/dL**, which is **well above** the hypoglycemia threshold (54 mg/dL).\n- There is **no evidence of a rapid decline** in glucose levels.\n- The **last insulin administration** is not clearly timed, but given the **high glucose level**, it is unlikely to result in hypoglycemia within the next hour.\n- No **symptoms or risk factors** (e.g., renal impairment, hypoglycemia unawareness, sulfonylurea use) suggest an imminent hypoglycemic event.\n\n---\n\n### **Final Prediction**\nPrediction: No, Risk: 0.15"
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": false,
            "TimeUpto": 2046110.0,
            "PredictedProb": 0.15,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n2046088.0 - sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 45.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.4\n2046093.0 - dornase alfa 1 MG/ML Inhalation Solution\n2046108.0 - Resp rate: 46.0;Body temperature: 97.5;BP dias: 93.0;Body temperature: 37.4;Q-T interval corrected: 459.0;Heart rate: 128.0;Q-T interval: 312.0;Heart rate: 134.0;BP sys: 159.0;Bdy temp measurement site: 4.0;BP sys: 161.0;BP mean: 115.0\n2046109.0 - chlorhexidine gluconate 1.2 MG/ML Mouthwash;acetaminophen 500 MG Oral Tablet\n2046110.0 - oxycodone hydrochloride 5 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### Analysis of the Patient Data\n\nThe provided data spans a sequence of EHR entries, with timestamps representing minutes from the first recorded event. The key to predicting hypoglycemia is to identify the **most recent glucose measurement**, assess **trends in glucose levels**, and evaluate **risk and protective factors** such as **medications**, **symptoms**, and **clinical context**.\n\n---\n\n### 1. **Most Recent Glucose Measurement**\n- The last glucose measurement is at **2045920.0 (minutes from first entry)**:  \n  **Glucose Bld-mCnc: 257.0 mg/dL (7.1 mmol/L)**  \n  This is a **high blood glucose level**, not indicating hypoglycemia.\n\n---\n\n### 2. **Trends in Glucose Levels**\n- The most recent glucose reading is 257 mg/dL (7.1 mmol/L), which is **not trending downward** toward hypoglycemia.\n- The prior glucose reading was at **2045659.0 (minutes from first entry)**:  \n  **Glucose Bld-mCnc: 307.0 mg/dL (8.5 mmol/L)**  \n  This indicates a **decline from 307 to 257 mg/dL**, but the **rate of decline is slow** and the **absolute level is still well above hypoglycemic thresholds**.\n\n---\n\n### 3. **Medications**\n- The patient is receiving **insulin isophane (NPH)** and **insulin regular**, both of which are **insulin types associated with hypoglycemic risk**.\n- However, **no specific timing or dose** of the most recent insulin administration is provided in the data, so it's unclear if the current glucose level is in response to recent insulin.\n- No **sulfonylureas** or other hypoglycemic agents are noted in the most recent records.\n\n---\n\n### 4. **Symptoms and Clinical Context**\n- No symptoms of hypoglycemia (e.g., sweating, confusion, dizziness) are reported in the most recent notes.\n- The patient has **no documented history of hypoglycemia** or hypoglycemia unawareness in the provided data.\n- There are **no signs of renal or hepatic impairment** that would increase hypoglycemic risk.\n\n---\n\n### 5. **Protective Factors**\n- The **most recent glucose is 257 mg/dL**, well above the hypoglycemic threshold.\n- The **rate of decline is slow**, and the **absolute value is not close to 54 mg/dL**.\n- No evidence of **fasting, exercise, or missed meals** that could increase hypoglycemic risk.\n- No **recent carbohydrate restriction** or **insulin overdose** is noted.\n\n---\n\n### 6. **Risk Synthesis & Prediction**\n- While the patient is on **insulin therapy**, which increases hypoglycemic risk, the **most recent glucose level is elevated**, and there is **no indication of rapid decline** toward hypoglycemia.\n- There are **no symptoms or risk factors** (e.g., hypoglycemia unawareness, renal impairment) to suggest an imminent hypoglycemic event.\n- Based on the current data, the **likelihood of a blood glucose level < 54 mg/dL within the next hour is low**.\n\n---\n\n### Final Prediction\n**Prediction: No, Risk: 0.15**  \nThe patient is at **low risk** of hypoglycemia in the next hour."
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046158.0,
            "PredictedProb": 0.85,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n2046088.0 - sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 45.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.4\n2046093.0 - dornase alfa 1 MG/ML Inhalation Solution\n2046108.0 - Resp rate: 46.0;Body temperature: 97.5;BP dias: 93.0;Body temperature: 37.4;Q-T interval corrected: 459.0;Heart rate: 128.0;Q-T interval: 312.0;Heart rate: 134.0;BP sys: 159.0;Bdy temp measurement site: 4.0;BP sys: 161.0;BP mean: 115.0\n2046109.0 - chlorhexidine gluconate 1.2 MG/ML Mouthwash;acetaminophen 500 MG Oral Tablet\n2046110.0 - oxycodone hydrochloride 5 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet\n2046158.0 - Procedure note\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### Analysis of the Patient Data\n\n#### 1. **Recent Glucose Readings and Trends**\n- **2044879.0 - Glucose Bld-mCnc: 85.0 mg/dL**  \n  This is a relatively low glucose level and is near the hypoglycemic threshold (54 mg/dL).\n  \n- **2045213.0 - Glucose Bld-mCnc: 142.0 mg/dL**  \n  This is a normal glucose level and suggests no hypoglycemia at this point.\n\n- **2045659.0 - Glucometer blood sugar; Glucose Bld-mCnc: 307.0 mg/dL**  \n  This is a very high glucose level, indicating hyperglycemia. This may suggest poor glycemic control or recent carbohydrate intake.\n\n- **2045920.0 - Glucose Bld-mCnc: 257.0 mg/dL**  \n  This is still high, but lower than the previous reading, suggesting a potential decline in glucose levels.\n\n**Trend Summary:**  \nGlucose levels have dropped from 307 mg/dL to 257 mg/dL, and then to 85 mg/dL. The most recent reading (85 mg/dL) is very close to the hypoglycemic threshold (54 mg/dL), and if the trend continues, the patient may experience hypoglycemia within the next hour.\n\n---\n\n#### 2. **Medications and Insulin Use**\n- **Insulin isophane (NPH), human 100 UNT/ML Injectable Suspension**  \n  This is a long-acting insulin that can cause hypoglycemia if not balanced with food or other glucose sources. It is used multiple times in the data.\n\n- **Insulin, regular, human 100 UNT/ML Injectable Solution**  \n  This is a short-acting insulin and can cause rapid drops in blood glucose if administered without sufficient food or glucose intake.\n\n- **No clear documentation of food intake or carbohydrate consumption** in the time window near the last glucose measurement (85 mg/dL), which raises concern about the risk of hypoglycemia.\n\n---\n\n#### 3. **Other Risk Factors**\n- **Renal function:**  \n  Creatinine levels are normal (0.47\u20130.51 mg/dL), indicating good renal function. This reduces the risk of impaired insulin clearance, which could otherwise increase hypoglycemia risk.\n\n- **No reported symptoms of hypoglycemia** (e.g., sweating, confusion, dizziness, etc.) in the most recent data.\n\n- **No documented hypoglycemic unawareness or prior hypoglycemic events** in the provided history, though the patient has had multiple glucose measurements in both hyper- and hypoglycemic ranges.\n\n---\n\n#### 4. **Protective Factors**\n- The patient has had episodes of **hyperglycemia**, suggesting that they may have a history of variable glucose control.\n- No evidence of **recent food intake** or **carbohydrate administration** is documented in the last few entries.\n- No **glucose-raising interventions** (e.g., oral glucose, IV dextrose) are noted in the most recent data.\n\n---\n\n#### 5. **Risk Synthesis & Prediction**\n- The most recent glucose level is **85 mg/dL**, which is **very close to the hypoglycemic threshold (54 mg/dL)**.\n- The patient is on **insulin therapy**, both long-acting and short-acting, which increases the risk of hypoglycemia.\n- There is **no documented carbohydrate intake or food consumption** in the recent time frame.\n- The **trend shows a decline** in glucose levels, which is concerning.\n- No protective factors (e.g., food, glucose-raising medications, or interventions) are noted in the last recorded data.\n\n---\n\n### Final Prediction\nGiven the **rapid decline in glucose**, the **use of insulin**, and the **lack of documented food intake or glucose-raising interventions**, the patient is at **high risk** of hypoglycemia (blood glucose < 54 mg/dL) within the next hour.\n\n**Prediction: Yes, Risk: 0.85**"
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": false,
            "TimeUpto": 2046168.0,
            "PredictedProb": 0.15,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n2046088.0 - sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 45.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.4\n2046093.0 - dornase alfa 1 MG/ML Inhalation Solution\n2046108.0 - Resp rate: 46.0;Body temperature: 97.5;BP dias: 93.0;Body temperature: 37.4;Q-T interval corrected: 459.0;Heart rate: 128.0;Q-T interval: 312.0;Heart rate: 134.0;BP sys: 159.0;Bdy temp measurement site: 4.0;BP sys: 161.0;BP mean: 115.0\n2046109.0 - chlorhexidine gluconate 1.2 MG/ML Mouthwash;acetaminophen 500 MG Oral Tablet\n2046110.0 - oxycodone hydrochloride 5 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet\n2046158.0 - Procedure note\n2046168.0 - Q-T interval: 336.0;Heart rate: 120.0;BP dias: 80.0;Glasgow coma scale: 11.0;BP sys: 127.0;Q-T interval corrected: 483.0;BP mean: 96.0;BP sys: 125.0\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### Step-by-Step Analysis\n\n---\n\n#### **1. Analyze Recent Data Points**\n\nWe focus on the **most recent glucose measurements** and their **trends**:\n\n- **2044879.0 - Glucose Bld-mCnc: 85.0 mg/dL**\n- **2045213.0 - Glucose Bld-mCnc: 142.0 mg/dL**\n- **2045659.0 - Glucose Bld-mCnc: 307.0 mg/dL**\n- **2045920.0 - Glucose Bld-mCnc: 257.0 mg/dL**\n- **2045916.0 - Glucose SerPl-mCnc: 234.0 mg/dL**\n- **2044492.0 - Glucose Bld-mCnc: 177.0 mg/dL**\n- **2044153.0 - Glucose Bld-mCnc: 231.0 mg/dL**\n\nThe **most recent glucose reading is 257.0 mg/dL** (at 2045920.0), and it has **decreased from 307 mg/dL** (at 2045659.0) and **234 mg/dL** (at 2045916.0). The trend is **not showing a rapid decline**, but rather **moderate fluctuation**.\n\n- **Rate of change**: The glucose levels are **not approaching the hypoglycemic threshold (54 mg/dL)** at any point in the recent history.\n- **No signs of imminent drop** within the next hour based on the observed trend.\n\n---\n\n#### **2. Identify Risk Factors**\n\n**Medications:**\n- **Insulin isophane (NPH)** and **insulin regular** are used multiple times in the record. These are **long- and short-acting insulins**, respectively.\n- **Timing of insulin administration** is not clearly specified, but **multiple insulin injections** are documented.\n- **No recent insulin administration** is explicitly mentioned close to the last glucose reading (2045920.0), suggesting **no recent bolus or rapid-acting insulin use**.\n\n**Comorbidities:**\n- **Normal renal function** (Creatinine: 0.47 to 0.51 mg/dL), so **no renal impairment** affecting insulin clearance.\n- **No mention of hypoglycemia unawareness** or **prior hypoglycemic events**.\n\n**Other labs:**\n- **Hemoglobin A1c** is not explicitly listed, but the glucose levels suggest **no recent overtreatment** or **hyperglycemic crisis**.\n- **No signs of impaired counter-regulatory hormone response** (e.g., glucagon levels not reported).\n\n**Symptoms:**\n- **No symptoms of hypoglycemia** (e.g., sweating, shakiness, confusion, dizziness) are reported in the recent entries.\n\n---\n\n#### **3. Consider Protective Factors**\n\n- **Recent glucose levels** are in the **hyperglycemic range**, with the last recorded at **257 mg/dL**.\n- **No signs of hypoglycemia** in the past 24 hours.\n- **No recent meals or dietary intake** that could trigger hypoglycemia are reported.\n- **No hypoglycemic agents** (e.g., sulfonylureas) are listed in the medication history.\n- **No symptoms or signs of hypoglycemia** are present in the most recent clinical notes.\n\n---\n\n#### **4. Risk Synthesis & Prediction**\n\n- The **last glucose reading is 257 mg/dL**, which is **well above the hypoglycemic threshold**.\n- The **trend is not showing a rapid decline**, and there is **no indication of an imminent drop** to < 54 mg/dL.\n- **No recent insulin administration**, **no hypoglycemic symptoms**, and **no other risk factors** are present.\n- The **risk of hypoglycemia in the next hour is low**.\n\n---\n\n### Final Prediction\n\n**Prediction: No, Risk: 0.15**"
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": false,
            "TimeUpto": 2046177.0,
            "PredictedProb": null,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n2043768.0 - BP mean: 75.0;BP sys: 108.0;Q-T interval corrected: 509.0;BP dias: 58.0;Q-T interval: 400.0\n2043776.0 - Resp rate: 38.0;albuterol 0.83 MG/ML Inhalation Solution;Heart rate: 97.0\n2043805.0 - Glucose Bld-mCnc: 126.0\n2043808.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2043828.0 - Q-T interval: 408.0;BP sys: 86.0;BP sys: 114.0;Q-T interval corrected: 500.0;Heart rate: 91.0;BP mean: 77.0;Heart rate: 92.0;BP dias: 59.0;Resp rate: 27.0\n2043888.0 - Q-T interval corrected: 506.0;BP sys: 90.0;BP sys: 76.0;Resp rate: 37.0;BP mean: 61.0;Heart rate: 102.0;BP dias: 47.0;Q-T interval: 384.0\n2043923.0 - suvorexant 20 MG Oral Tablet\n2043948.0 - Phosphate SerPl-sCnc;Glasgow coma scale: 11.0;BP sys: 77.0;CBC Pnl;Resp rate: 40.0;Body temperature: 98.7;Measurement of ionized calcium in blood specimen;BP mean: 70.0;BP sys: 101.0;Q-T interval corrected: 503.0;Bas Metab 2000 Pnl SerPl;Body temperature: 37.1;Magnesium SerPl-sCnc;BP dias: 54.0;Heart rate: 106.0;Complete blood count without differential\n2043963.0 - Heart rate: 98.0\n2043964.0 - Body height: 65.98;Resp rate: 30.0;PEEP on vent Respiratory: 5.0\n2044008.0 - Resp rate: 22.0;BP dias: 63.0;Q-T interval corrected: 521.0;BP sys: 106.0;Heart rate: 89.0;BP mean: 77.0;Heart rate: 90.0;Q-T interval: 408.0\n2044027.0 - gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet\n2044068.0 - Q-T interval corrected: 513.0;Heart rate: 81.0;BP dias: 53.0;Q-T interval: 424.0;BP mean: 66.0;Resp rate: 23.0;BP sys: 91.0\n2044108.0 - haloperidol 5 MG/ML Injectable Solution\n2044128.0 - Heart rate: 92.0;BP mean: 81.0;Q-T interval corrected: 493.0;Resp rate: 35.0;Q-T interval: 400.0;Heart rate: 91.0;BP dias: 65.0;BP sys: 112.0\n2044143.0 - Resp rate: 32.0;Heart rate: 94.0\n2044153.0 - Glucose Bld-mCnc: 231.0\n2044187.0 - 150 ML sodium chloride 9 MG/ML Injection;Resp rate: 38.0;suvorexant 10 MG Oral Tablet;BP sys: 107.0;meropenem 1000 MG Injection;15 ML sodium phosphate, dibasic 142 MG/ML / sodium phosphate, monobasic 276 MG/ML Injection;10 ML calcium chloride 100 MG/ML Prefilled Syringe;Body temperature: 98.5;Q-T interval corrected: 495.0;Body temperature: 36.9;glucose 50 MG/ML Injectable Solution;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution\n2044203.0 - Change of dressing\n2044248.0 - Resp rate: 24.0;BP mean: 59.0;Heart rate: 73.0;BP sys: 89.0;Q-T interval corrected: 498.0;Q-T interval: 448.0;BP dias: 44.0;Heart rate: 72.0\n2044258.0 - BP sys: 107.0\n2044308.0 - Q-T interval: 424.0;BP sys: 110.0;Heart rate: 97.0;Resp rate: 40.0;Q-T interval corrected: 525.0\n2044368.0 - BP sys: 104.0;Heart rate: 93.0;Q-T interval corrected: 493.0;Resp rate: 39.0;BP mean: 77.0;Q-T interval: 392.0;BP sys: 112.0;BP dias: 63.0\n2044428.0 - BP dias: 52.0;BP mean: 68.0;Bdy temp measurement site: 1.0;Resp rate: 22.0;BP sys: 111.0;Q-T interval: 432.0;Heart rate: 80.0;BP sys: 99.0;Q-T interval corrected: 511.0;Body temperature: 98.5;Heart rate: 76.0;Body temperature: 36.9\n2044444.0 - Resp rate: 24.0\n2044446.0 - Phosphate SerPl-mCnc: 2.5;Anion Gap SerPl Calc-sCnc: 7.0;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 108.0;Hgb Bld-mCnc: 9.2;WBC  Spec Auto: 9.0;pO2 temp adj Bld: 62.0;BUN SerPl-mCnc: 10.0;Base excess Bld Calc-sCnc: 8.0;SaO2 % Bld from pO2: 93.0;MCHC RBC Auto-EntMCnc: 30.9;Potassium SerPl-sCnc: 4.3;MCH RBC Qn Auto: 29.4;Glucose SerPl-mCnc: 184.0;HCO3 Spec-sCnc: 31.8;Gas Pnl BldA;Chloride SerPl-sCnc: 103.0;Platelet: 272.0;Magnesium SerPl-mCnc: 2.0;pCO2 temp adj Bld: 43.1;Creat SerPl-mCnc: 0.47;Sodium SerPl-sCnc: 139.0;pH temp adj Bld: 7.48;Ca-I SerPl-mCnc: 1.13;Calcium SerPl-mCnc: 8.4;Hct VFr: 29.8;CO2 BldA-sCnc: 33.0;pH SerPl: 7.51;RBC: 3.13;CO2 SerPl-sCnc: 29.0;RDW RBC Auto: 16.2;RBC Auto: 95.2\n2044488.0 - Heart rate: 80.0;Q-T interval: 456.0;Q-T interval corrected: 510.0;BP sys: 110.0;Resp rate: 26.0;Heart rate: 79.0\n2044489.0 - midodrine hydrochloride 5 MG Oral Tablet\n2044492.0 - Glucometer blood sugar;Glucose Bld-mCnc: 177.0\n2044493.0 - insulin, regular, human 100 UNT/ML Injectable Solution\n2044548.0 - Heart rate: 94.0;Q-T interval: 408.0;Heart rate: 95.0;BSA: 1.76;Resp rate: 40.0;Weight: 2338.64;Q-T interval corrected: 511.0;BP sys: 111.0\n2044608.0 - Q-T interval corrected: 509.0;BP sys: 108.0;Pain severity Score VAS: 0.0;Q-T interval: 392.0;Resp rate: 39.0;Heart rate: 96.0\n2044651.0 - Prog note\n2044658.0 - Heart rate: 102.0;sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 32.0;albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution\n2044668.0 - Resp rate: 34.0;Heart rate: 94.0;Q-T interval: 400.0;Q-T interval corrected: 506.0;Heart rate: 92.0\n2044675.0 - guanfacine 1 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet;chlorhexidine gluconate 1.2 MG/ML Mouthwash\n2044728.0 - Resp rate: 39.0;Heart rate: 104.0;Q-T interval corrected: 514.0;BP sys: 128.0;Q-T interval: 392.0;Heart rate: 103.0\n2044784.0 - PEEP on vent Respiratory: 5.0;Resp rate: 31.0\n2044788.0 - BP sys: 117.0;Q-T interval corrected: 506.0;Heart rate: 102.0;Resp rate: 35.0;Heart rate: 103.0\n2044798.0 - BP sys: 113.0;Q-T interval: 408.0;Heart rate: 92.0;Resp rate: 21.0;Q-T interval corrected: 511.0\n2044848.0 - Resp rate: 37.0;BP sys: 123.0;Q-T interval: 384.0;Q-T interval corrected: 506.0;Prog note;Heart rate: 104.0\n2044878.0 - dornase alfa 1 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.2;Resp rate: 22.0\n2044879.0 - Glucose Bld-mCnc: 85.0\n2044880.0 - Procedure note\n2044895.0 - Procedure note\n2044908.0 - Resp rate: 32.0;Heart rate: 91.0;BP sys: 157.0;Q-T interval: 424.0;Q-T interval corrected: 513.0;Glasgow coma scale: 14.0;Heart rate: 90.0\n2044926.0 - Prog note\n2044968.0 - Resp rate: 28.0;BP sys: 92.0;BP mean: 77.0;BP sys: 107.0;Heart rate: 88.0;BP dias: 62.0;Heart rate: 87.0;Q-T interval corrected: 508.0\n2045002.0 - pH measurement, venous: 7.4;HCO3 BldV-sCnc: 30.6;CO2 BldV-sCnc: 32.0;Venous oxygen saturation measurement: 64.0;Base excess Bld Calc-sCnc: 6.0;pO2 BldV: 34.0;Measurement of venous partial pressure of carbon dioxide: 49.8;Gas Pnl Bld\n2045028.0 - Q-T interval: 408.0;Heart rate: 94.0;BP sys: 102.0;Q-T interval corrected: 511.0;Resp rate: 31.0;BP dias: 64.0;BP sys: 98.0\n2045073.0 - Consult note\n2045088.0 - BP dias: 70.0;Q-T interval: 400.0;Heart rate: 96.0;BP sys: 111.0;BP sys: 116.0;Resp rate: 40.0;Q-T interval corrected: 506.0;BP mean: 84.0\n2045108.0 - Resp rate: 36.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 53.0\n2045134.0 - Procedure note\n2045148.0 - Resp rate: 34.0;BP sys: 75.0;BP sys: 99.0;BP mean: 71.0;BP dias: 57.0;Q-T interval corrected: 511.0;Q-T interval: 392.0;Heart rate: 104.0\n2045157.0 - Consult note\n2045208.0 - Q-T interval: 360.0;BP mean: 97.0;Heart rate: 110.0;BP dias: 84.0;Q-T interval corrected: 485.0;Resp rate: 24.0;BP sys: 122.0\n2045213.0 - Glucose Bld-mCnc: 142.0\n2045218.0 - insulin isophane, human 100 UNT/ML Injectable Suspension\n2045268.0 - Q-T interval corrected: 494.0;Resp rate: 41.0;BP mean: 67.0;Heart rate: 112.0;BP sys: 58.0;Heart rate: 113.0;BP dias: 58.0;BP sys: 85.0\n2045328.0 - BP sys: 111.0;BP mean: 79.0;Q-T interval: 352.0;Q-T interval corrected: 485.0;BP sys: 99.0;BP dias: 63.0;Resp rate: 43.0\n2045388.0 - Heart rate: 108.0;BP mean: 71.0;Body temperature: 98.2;Phosphate SerPl-sCnc;Resp rate: 35.0;Measurement of ionized calcium in blood specimen;BP sys: 96.0;Q-T interval: 376.0;CBC Pnl;Complete blood count without differential;BP sys: 98.0;Magnesium SerPl-sCnc;Q-T interval corrected: 504.0;Bas Metab 2000 Pnl SerPl;BP dias: 58.0;Body temperature: 36.8\n2045393.0 - Heart rate: 105.0;Resp rate: 40.0\n2045394.0 - Heart rate: 106.0;Resp rate: 36.0\n2045395.0 - PEEP on vent Respiratory: 5.0;Heart rate: 104.0\n2045433.0 - ABO and Rho typing\n2045448.0 - BP sys: 100.0;gabapentin 600 MG Oral Tablet;ramelteon 8 MG Oral Tablet;BP sys: 93.0;Resp rate: 40.0;BP dias: 55.0;Heart rate: 111.0;Q-T interval corrected: 507.0;BP mean: 68.0;Heart rate: 110.0\n2045449.0 - haloperidol 5 MG/ML Injectable Solution;suvorexant 20 MG Oral Tablet\n2045508.0 - Heart rate: 110.0;BP dias: 66.0;Q-T interval: 360.0;BP sys: 113.0;BP sys: 120.0;Q-T interval corrected: 487.0;BP mean: 82.0\n2045568.0 - BP sys: 107.0;Q-T interval: 368.0;Heart rate: 111.0;BP sys: 104.0;Q-T interval corrected: 503.0;BP dias: 59.0;Heart rate: 112.0;Resp rate: 34.0;BP mean: 74.0\n2045627.0 - Q-T interval: 456.0;sulfamethoxazole 80 MG/ML / trimethoprim 16 MG/ML Injectable Solution;Resp rate: 24.0;Body temperature: 36.9;Body temperature: 98.5;Q-T interval corrected: 527.0;suvorexant 10 MG Oral Tablet;BP mean: 77.0;glucose 50 MG/ML Injectable Solution;meropenem 1000 MG Injection;Heart rate: 71.0;BP sys: 92.0;BP dias: 70.0\n2045643.0 - Weight\n2045659.0 - Glucometer blood sugar;Glucose Bld-mCnc: 307.0\n2045660.0 - insulin isophane, human 100 UNT/ML Injectable Suspension;insulin, regular, human 100 UNT/ML Injectable Solution\n2045676.0 - Heart rate: 106.0;PEEP on vent Respiratory: 5.0;Resp rate: 32.0\n2045688.0 - BP sys: 93.0;Resp rate: 38.0;Q-T interval corrected: 494.0;BP dias: 57.0;Heart rate: 108.0;Q-T interval: 368.0;BP sys: 72.0;BP mean: 69.0\n2045748.0 - BP mean: 70.0;Q-T interval: 360.0;Heart rate: 111.0;BP sys: 98.0;Q-T interval corrected: 490.0;Resp rate: 34.0;BP sys: 97.0\n2045760.0 - Heart rate: 106.0;Resp rate: 38.0\n2045808.0 - Resp rate: 37.0;BP sys: 99.0;Heart rate: 111.0;BP sys: 95.0;Q-T interval corrected: 501.0;Q-T interval: 368.0\n2045868.0 - BP sys: 93.0;Resp rate: 38.0;BP sys: 91.0;Bdy temp measurement site: 1.0;BP dias: 54.0;BP mean: 66.0;Heart rate: 106.0;Body temperature: 36.8;Glasgow coma scale: 14.0;Q-T interval corrected: 496.0;Body temperature: 98.2;Heart rate: 107.0\n2045893.0 - Resp rate: 30.0;Heart rate: 110.0\n2045915.0 - ABO and Rho typing\n2045916.0 - RDW RBC Auto: 16.4;Calcium SerPl-mCnc: 8.2;Anion Gap SerPl Calc-sCnc: 10.0;Phosphate SerPl-mCnc: 2.2;GFR SerPlBld Creatinine-bsd fmla CKD-EPI: 105.0;Sodium SerPl-sCnc: 135.0;pH SerPl: 7.37;MCH RBC Qn Auto: 29.3;Hct VFr: 29.0;RBC: 3.07;Glucose SerPl-mCnc: 234.0;RBC Auto: 94.5;Bld gp Ab Scn SerPl Ql: NEG;Potassium SerPl-sCnc: 4.6;Platelet: 265.0;BUN SerPl-mCnc: 12.0;CO2 SerPl-sCnc: 28.0;Chloride SerPl-sCnc: 97.0;Magnesium SerPl-mCnc: 1.9;Creat SerPl-mCnc: 0.51;Ca-I SerPl-mCnc: 1.16;WBC  Spec Auto: 14.4;ABO + Rh Bld;Hgb Bld-mCnc: 9.0;MCHC RBC Auto-EntMCnc: 31.0\n2045920.0 - Glucose Bld-mCnc: 257.0\n2045928.0 - BP sys: 110.0;BP mean: 79.0;Resp rate: 25.0;BP dias: 63.0;Q-T interval corrected: 507.0;Heart rate: 116.0;BP sys: 106.0;Heart rate: 113.0\n2045936.0 - Q-T interval corrected: 503.0;BP sys: 100.0;Resp rate: 39.0;midodrine hydrochloride 5 MG Oral Tablet\n2045988.0 - BP mean: 82.0;BP sys: 88.0;BP sys: 115.0;Q-T interval: 360.0;Heart rate: 113.0;Heart rate: 114.0;Q-T interval corrected: 496.0;Resp rate: 40.0;BP dias: 66.0\n2045990.0 - Prog note\n2046048.0 - Heart rate: 113.0;BP dias: 84.0;BP sys: 95.0;BP sys: 139.0;Q-T interval corrected: 487.0;Resp rate: 29.0;Heart rate: 115.0;Q-T interval: 352.0;BP mean: 102.0\n2046088.0 - sodium chloride 70 MG/ML Inhalation Solution;Resp rate: 45.0;albuterol 0.83 MG/ML Inhalation Solution;PEEP on vent Respiratory: 5.4\n2046093.0 - dornase alfa 1 MG/ML Inhalation Solution\n2046108.0 - Resp rate: 46.0;Body temperature: 97.5;BP dias: 93.0;Body temperature: 37.4;Q-T interval corrected: 459.0;Heart rate: 128.0;Q-T interval: 312.0;Heart rate: 134.0;BP sys: 159.0;Bdy temp measurement site: 4.0;BP sys: 161.0;BP mean: 115.0\n2046109.0 - chlorhexidine gluconate 1.2 MG/ML Mouthwash;acetaminophen 500 MG Oral Tablet\n2046110.0 - oxycodone hydrochloride 5 MG Oral Tablet;lansoprazole 30 MG Disintegrating Oral Tablet;apixaban 5 MG Oral Tablet\n2046158.0 - Procedure note\n2046168.0 - Q-T interval: 336.0;Heart rate: 120.0;BP dias: 80.0;Glasgow coma scale: 11.0;BP sys: 127.0;Q-T interval corrected: 483.0;BP mean: 96.0;BP sys: 125.0\n2046177.0 - Procedure note\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "### **Step-by-Step Analysis of the Patient Data**\n\n---\n\n#### **1. Analyze Recent Data Points**\n\nLet's focus on the most recent data entries to assess trends and potential risk factors for hypoglycemia.\n\n- **2046168.0**  \n  - BP sys: 127.0, BP mean: 96.0, BP dias: 80.0  \n  - Q-T interval: 336.0, Q-T interval corrected: 483.0  \n  - Heart rate: 120.0  \n  - Glasgow coma scale: 11.0  \n  - **No glucose measurement reported.**\n\n- **2046110.0**  \n  - Medications: oxycodone, lansoprazole, apixaban  \n  - No glucose measurement reported.\n\n- **2046108.0**  \n  - Resp rate: 46.0  \n  - BP dias: 93.0, BP sys: 159.0, BP mean: 115.0  \n  - Q-T interval: 312.0, Q-T interval corrected: 459.0  \n  - Heart rate: 134.0  \n  - Body temperature: 37.4  \n  - **No glucose measurement reported.**\n\n- **2046093.0**  \n  - dornase alfa 1 MG/ML Inhalation Solution  \n  - **No glucose measurement reported.**\n\n- **2046088.0**  \n  - albuterol 0.83 MG/ML Inhalation Solution  \n  - sodium chloride 70 MG/ML Inhalation Solution  \n  - PEEP on vent Respiratory: 5.4  \n  - Resp rate: 45.0  \n  - **No glucose measurement reported.**\n\n- **2046048.0**  \n  - BP sys: 139.0, BP dias: 84.0, BP mean: 102.0  \n  - Q-T interval: 352.0, Q-T interval corrected: 487.0  \n  - Resp rate: 29.0  \n  - Heart rate: 115.0  \n  - **No glucose measurement reported.**\n\n- **2045990.0**  \n  - Prog note  \n  - **No glucose measurement reported.**\n\n- **2045988.0**  \n  - BP sys: 115.0, BP dias: 66.0, BP mean: 82.0  \n  - Q-T interval: 360.0, Q-T interval corrected: 496.0  \n  - Resp rate: 40.0  \n  - Heart rate: 114.0  \n  - **No glucose measurement reported.**\n\n- **2045936.0**  \n  - Q-T interval corrected: 503.0  \n  - BP sys: 100.0  \n  - Resp rate: 39.0  \n  - midodrine hydrochloride 5 MG Oral Tablet  \n  - **No glucose measurement reported.**\n\n- **2045928.0**  \n  - BP sys: 106.0, BP dias: 63.0, BP mean: 79.0  \n  - Resp rate: 25.0  \n  - Q-T interval corrected: 507.0  \n  - Heart rate: 116.0  \n  - **No glucose measurement reported.**\n\n- **2045920.0**  \n  - **Glucose Bld-mCnc: 257.0 mg/dL (7.1 mmol/L)**  \n    - This is **elevated**, but still in the hyperglycemic range.  \n    - No trend of decline is observed from this point.\n\n- **2045916.0**  \n  - Glucose SerPl-mCnc: 234.0 mg/dL (6.5 mmol/L)  \n    - Also **elevated**, but still not declining.\n\n- **2045893.0**  \n  - Resp rate: 30.0  \n  - Heart rate: 110.0  \n  - **No glucose measurement reported.**\n\n- **2045868.0**  \n  - BP sys: 93.0, BP dias: 54.0, BP mean: 66.0  \n  - Resp rate: 38.0  \n  - Q-T interval corrected: 496.0  \n  - Heart rate: 107.0  \n  - **No glucose measurement reported.**\n\n- **2045808.0**  \n  - Resp rate: 37.0  \n  - BP sys: 99.0  \n  - Heart rate: 111.0  \n  - Q-T interval corrected: 501.0  \n  - **No glucose measurement reported.**\n\n- **2045760.0**  \n  - Heart rate: 106.0  \n  - Resp rate: 38.0  \n  - **No glucose measurement reported.**\n\n- **2045748.0**  \n  - BP sys: 98.0, BP mean: 70.0  \n  - Resp rate: 34.0  \n  - Q-T interval corrected: 490.0  \n  - Heart rate: 111.0  \n  - **No glucose measurement reported.**\n\n- **2045688.0**  \n  - BP sys: 93.0, BP dias: 57.0, BP mean: 69.0  \n  - Resp rate: 38.0  \n  - Q-T interval corrected: 494.0  \n  - Heart rate: 108.0  \n  - **No glucose measurement reported.**\n\n- **2045660.0**  \n  - **Insulin isophane, human 100 UNT/ML Injectable Suspension**  \n  - **Insulin, regular, human 100 UNT/ML Injectable Solution**  \n    - These are **long-acting** and **short-acting** insulins, respectively.  \n    - Suggests the patient is on **intensive insulin therapy**.  \n    - **High risk of hypoglycemia** if not carefully monitored.\n\n- **2045659.0**  \n  - **Glucometer blood sugar; Glucose Bld-mCnc: 307.0 mg/dL (8.5 mmol/L)**  \n    - **Significantly elevated**, indicating **hyperglycemia**.  \n    - No evidence of a downward trend.\n\n- **2045643.0**  \n  - Weight recorded  \n  - **No glucose measurement reported.**\n\n- **2045627.0**  \n  - BP sys: 107.0, BP dias: 59.0, BP mean: 74.0  \n  - Q-T interval corrected: 503.0  \n  - Resp rate: 34.0  \n  - Heart rate: 112.0  \n  - **No glucose measurement reported.**\n\n- **2045568.0**  \n  - BP sys: 107.0, BP dias: 59.0, BP mean: 74.0  \n  - Q-T interval corrected: 503.0  \n  - Resp rate: 34.0  \n  - Heart rate: 112.0  \n  - **No glucose measurement reported.**\n\n- **2045508.0**  \n  - BP sys: 113.0, BP dias: 66.0, BP mean: 82.0  \n  - Q-T interval corrected: 487.0  \n  - Resp rate: 29.0  \n  - Heart rate: 110.0  \n  - **No glucose measurement reported.**\n\n- **2045449.0**  \n  - haloperidol 5 MG/ML Injectable Solution  \n  - suvorexant 20 MG Oral Tablet  \n  - **No glucose measurement reported.**\n\n- **2045448.0**  \n  - BP sys: 100.0, BP dias: 55.0, BP mean: 68.0  \n  - Resp rate: 40.0  \n  - Q-T interval corrected: 507.0  \n  - Heart rate: 110.0  \n  - gabapentin 600 MG Oral Tablet  \n  - suvorexant 20 MG Oral Tablet  \n  - **No glucose measurement reported.**\n\n- **2045395.0**  \n  - PEEP on vent Respiratory: 5.0  \n  - Heart rate: 104.0  \n  - **No glucose measurement reported.**\n\n- **2045"
        },
        {
            "CSN": 115967112,
            "TrueLabel": false,
            "PredictedLabel": false,
            "TimeUpto": 1362.0,
            "PredictedProb": 0.1,
            "TestPrompt": "<|im_start|>system\nYou are a medical AI assistant focused on predicting hypoglycemic events in outpatient settings. Your primary task is to analyze provided Electronic Health Record (EHR) data to assess the likelihood of a patient experiencing hypoglycemia (blood glucose < 3 mmol/L or < 54 mg/dL) within the next hour from the last recorded data point.\n\nThe input will be a chronologically ordered sequence of patient data from outpatient visits and monitoring. Each entry follows the format: <time_stamp>: <data>, where <time_stamp> denotes the relative time in minutes starting from the first visit. The data will include patient demographics, medical history, current medications (especially diabetes medications), recent blood glucose measurements, dietary information, physical activity, and any symptoms reported.\n\nHypoglycemia is defined as a blood glucose level below 3 mmol/L (54 mg/dL) and can lead to serious consequences if not promptly addressed. Early identification is crucial for preventing severe hypoglycemic events, especially in outpatient settings where continuous medical supervision is not available.\n\nPay close attention to trends and critical factors in the following parameters, as they relate to hypoglycemia risk:\n\n* Rapidly declining laboratory values such as blood glucose (approaching the critical threshold of 3 mmol/L), hemoglobin A1c (indicating recent overtreatment), glucagon (showing impaired counter-regulatory response), and creatinine (suggesting reduced insulin clearance) serve as critical indicators to evaluate when assessing a patient's imminent risk of developing hypoglycemia.\n* **Medications:** Use of insulin (type, dose, timing of last dose), sulfonylureas, or other glucose-lowering medications. Note any recent changes in medication regimen.\n* **Patient History:** Previous hypoglycemic events, hypoglycemia unawareness, diabetes duration, comorbidities (especially renal or hepatic impairment).\n* **Reported Symptoms:** Any mention of symptoms that could indicate developing hypoglycemia (e.g., shakiness, sweating, hunger, confusion, irritability, dizziness, weakness).\n\n\nTo arrive at your prediction, follow these reasoning steps:\n1. **Analyze Recent Data Points:** Evaluate recent glucose readings for trends, focusing particularly on the rate and direction of change. Note the timing relative to meals, medication administration, and physical activity.\n2. **Identify Risk Factors:** Assess specific factors that may contribute to hypoglycemia risk in this patient at this time, such as medication timing/dosing, related labs, and any reported symptoms.\n3. **Consider Protective Factors:** Note any factors that might mitigate hypoglycemia risk, such as recent carbohydrate consumption or glucose-raising interventions.\n4. **Risk Synthesis & Prediction:** Combine all findings to determine the likelihood of the patient experiencing a blood glucose level below 3 mmol/L within the next hour. Consider the overall clinical picture, the rate of glucose decline (if present), and the confluence of risk factors.\n\nThink step-by-step, and then provide the answer. When writing your final answer, use the following format: \"Prediction: <Yes/No>, Risk: <0...1>\". 'Yes' indicates a high risk of hypoglycemia within the next hour, 'No' indicates a low risk, and 'Risk' is a numerical value between 0 (no risk) and 1 (high risk). For example, \"Prediction: Yes, Risk: 0.85\", indicates a high risk of hypoglycemia. Base your analysis SOLELY on the provided EHR text and your embedded medical knowledge.<|im_end|>\n<|im_start|>user\nUSER:Patient History:\n0.0 - XR Chest 1V\n15.0 - ABO + Rh Bld;Bld gp Ab Scn SerPl Ql: Negative\n17.0 - XR Should 1V;XR Pelvis 1V;XR Humerus 2V;Computed tomography of head and cervical spine\n23.0 - RDW RBC Auto: 13.4;Neutrophils: 5.53;Eosinophil: 0.21;Calcium SerPl-mCnc: 9.1;Basophils: 0.03;Lymphocytes: 2.97;Hgb Bld-mCnc: 15.2;Monocytes NFr: 7.2;RBC Auto: 91.7;Monocytes: 0.68;RBC: 5.05;WBC  Spec Auto: 9.4;Chloride SerPl-sCnc: 105.0;BUN SerPl-mCnc: 17.0;MCHC RBC Auto-EntMCnc: 32.7;Anion Gap SerPl Calc-sCnc: 8.0;Creat SerPl-mCnc: 1.2;Basophils NFr: 0.3;Glucose SerPl-mCnc: 128.0;Sodium SerPl-sCnc: 138.0;Potassium SerPl-sCnc: 4.5;Lymphocytes NFr: 31.6;Neutrophils NFr: 58.7;MCH RBC Qn Auto: 30.0;Eosinophil NFr: 2.2;Platelet: 197.0;Hct VFr: 46.4;CO2 SerPl-sCnc: 25.0\n26.0 - ED Note\n27.0 - 1 ML morphine sulfate 4 MG/ML Prefilled Syringe\n33.0 - 2 ML ondansetron 2 MG/ML Injection\n35.0 - Service Cmnt-Imp;Bas Metab 2000 Pnl SerPl;Specimen description;CBC W Diff pnl,unspecified Bld\n41.0 - ABO and Rho typing;Indirect Coombs test\n62.0 - Computed tomography of thorax, abdomen and pelvis with contrast\n63.0 - Consult note\n86.0 - XR Should-L 2V\n94.0 - No FSN found\n108.0 - ABO + Rh Bld Cfm\n161.0 - 12 lead electrocardiogram;EKG impression\n174.0 - ED Note\n199.0 - R-R interval: 561.0;P-R interval: 136.0;QRS dur: 74.0;Q-T interval: 324.0;P wave axis: 64.0;Q-T interval corrected: 393.0;Heart rate: 107.0;T wave axis: -12.0;QRS axis: 38.0\n224.0 - No FSN found\n240.0 - ED Note\n243.0 - Pain severity Score VAS: 10.0;Glasgow coma scale: 15.0;BP mean: 104.0;Heart rate: 112.0;BSA: 1.91;Q-T interval corrected: 0.46;BP dias: 94.0;Weight: 2736.0;Body height: 67.0;Resp rate: 20.0;BP sys: 125.0;Bdy temp measurement site: 1.0;Body temperature: 100.6;Q-T interval: 0.33\n264.0 - Assessment of cardiac status using monitoring device;naloxone hydrochloride 0.4 MG/ML Injectable Solution;Insertion of catheter into peripheral vein\n267.0 - Consult note\n273.0 - 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection\n288.0 - Q-T interval: 316.0;T wave axis: -27.0;Heart rate: 119.0;QRS axis: 55.0;Q-T interval corrected: 397.0;R-R interval: 504.0;QRS dur: 78.0;P-R interval: 107.0;P wave axis: 69.0\n422.0 - Snuff consumption: N;Body temperature: 98.6;Body surface area: 1.91;History of clinical finding in subject;User of smokeless tobacco;Diastolic blood pressure: 74.0;Systolic blood pressure: 137.0;Inhaled O2 flow rate: 97.0;Heart rate measured at systemic artery: 93.0;Cigar consumption: N;Tobacco user;Tobac smoke stat;EKG Study;Cigarette consumption: N;BMI: 26.78;Chewed tobacco consumption: N;Pipe tobacco consumption: N\n427.0 - Bdy temp measurement site: 1.0;Body temperature: 98.4;Q-T interval corrected: 0.42;BP dias: 91.0;BP mean: 104.0;Heart rate: 101.0;Q-T interval: 0.33;BP sys: 130.0;Resp rate: 18.0;Pain severity Score VAS: 2.0\n683.0 - Hgb Bld-mCnc: 13.4;Anion Gap SerPl Calc-sCnc: 6.0;CO2 SerPl-sCnc: 30.0;WBC  Spec Auto: 8.5;RBC Auto: 92.4;MCH RBC Qn Auto: 32.0;Calcium SerPl-mCnc: 8.4;Creat SerPl-mCnc: 1.2;MCHC RBC Auto-EntMCnc: 34.6;BUN SerPl-mCnc: 13.0;Sodium SerPl-sCnc: 141.0;RBC: 4.2;Platelet: 164.0;Hct VFr: 38.8;Chloride SerPl-sCnc: 105.0;Potassium SerPl-sCnc: 4.3;Glucose SerPl-mCnc: 141.0;RDW RBC Auto: 13.7\n693.0 - Heart rate: 122.0;BP sys: 143.0;Q-T interval: 0.36;Q-T interval corrected: 0.49;Body temperature: 98.8;BP mean: 108.0\n807.0 - XR Chest 1V\n839.0 - Dietary regime\n840.0 - 1 ML morphine sulfate 4 MG/ML Prefilled Syringe\n873.0 - Q-T interval corrected: 0.44;Q-T interval: 0.33\n893.0 - BP sys: 146.0;Q-T interval corrected: 402.0;Body temperature: 98.6;Heart rate: 105.0;BP dias: 87.0;BP mean: 107.0;Heart rate: 104.0;Resp rate: 20.0;Q-T interval: 344.0\n898.0 - acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet\n982.0 - 2 ML ondansetron 2 MG/ML Injection\n1007.0 - 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection\n1033.0 - Prog note\n1073.0 - H&P note\n1140.0 - Pain severity Score VAS: 4.0\n1362.0 - Resp rate: 18.0;BP sys: 142.0;BP dias: 95.0;Body temperature: 99.0;BP mean: 111.0\n\n\nAnalyze the patient first, and then provide your final prediction about hypoglycemia risk in the correct format.<|im_end|>\n<|im_start|>assistant\n<think>\n\n</think>\n\n",
            "ExtractedText": "**Analysis:**\n\nThe provided EHR data is extensive but lacks clear chronological context and does not focus on a single patient with a clear timeline of outpatient glucose monitoring. The data appears to be a collection of multiple clinical events, some of which may be from inpatient or emergency department (ED) visits, and it does not contain a clear sequence of outpatient glucose measurements or a specific focus on diabetes management.\n\nHowever, we can extract and analyze the relevant data for hypoglycemia risk:\n\n### 1. **Blood Glucose Levels:**\n- **Glucose SerPl-mCnc (mg/dL):**\n  - At **23.0 minutes**: 128.0 mg/dL\n  - At **683.0 minutes**: 141.0 mg/dL\n  - At **893.0 minutes**: Not recorded, but other vital signs are present.\n  - At **1007.0 minutes**: No glucose data.\n\nThere is no evidence of a declining glucose trend or values near hypoglycemic levels (i.e., < 54 mg/dL). The recorded glucose levels are within the normal to slightly elevated range for a diabetic patient, and no hypoglycemic event is reported.\n\n### 2. **Medications:**\n- **Morphine sulfate**, **ondansetron**, **acetaminophen/oxycodone**, and **glucose-containing IV fluids** are listed. There is no mention of insulin, sulfonylureas, or other glucose-lowering medications that would increase the risk of hypoglycemia.\n- The **1000 mL glucose 50 mg/mL IV solution** may suggest a recent administration of glucose, which would **decrease the risk** of hypoglycemia.\n\n### 3. **Patient History:**\n- There is no clear mention of diabetes or a history of hypoglycemic events.\n- No evidence of **renal or hepatic impairment** that could affect glucose metabolism.\n- No mention of **hypoglycemia unawareness**, a key risk factor for severe hypoglycemia.\n\n### 4. **Symptoms:**\n- **Pain severity** is reported at different times (e.g., 10/10, then 2/10, then 4/10), but no symptoms of hypoglycemia (e.g., sweating, confusion, dizziness) are reported.\n\n### 5. **Other Labs and Vitals:**\n- **Creatinine** is 1.2 mg/dL (normal to mildly elevated), suggesting **no significant renal impairment**.\n- **Sodium, potassium, and chloride** are within normal ranges.\n- **Heart rate** is elevated at times (e.g., 119, 122 bpm), but this is more consistent with pain or stress than hypoglycemia.\n\n---\n\n### **Risk Synthesis:**\n- No glucose values are approaching the hypoglycemic threshold.\n- No glucose-lowering medications are reported.\n- Glucose IV fluid administration is noted, which is protective.\n- No symptoms of hypoglycemia are reported.\n- No clear diabetes diagnosis or hypoglycemia history is present.\n\n---\n\n**Prediction: No, Risk: 0.1**  \nThe likelihood of hypoglycemia within the next hour is very low based on the available data."
        }
    ],
    "all_predictions": [
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046048.0,
            "PredictedProb": 0.8
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046088.0,
            "PredictedProb": 0.92
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046093.0,
            "PredictedProb": 0.85
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046108.0,
            "PredictedProb": 0.85
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": false,
            "TimeUpto": 2046109.0,
            "PredictedProb": 0.15
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": false,
            "TimeUpto": 2046110.0,
            "PredictedProb": 0.15
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": true,
            "TimeUpto": 2046158.0,
            "PredictedProb": 0.85
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": false,
            "TimeUpto": 2046168.0,
            "PredictedProb": 0.15
        },
        {
            "CSN": 115967106,
            "TrueLabel": true,
            "PredictedLabel": false,
            "TimeUpto": 2046177.0,
            "PredictedProb": null
        },
        {
            "CSN": 115967112,
            "TrueLabel": false,
            "PredictedLabel": false,
            "TimeUpto": 1362.0,
            "PredictedProb": 0.1
        }
    ]
}